semaglutide phase 3 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, trial The evoke and evoke+ phase

Gastrointestinal Effects The most frequently reported adverse reactions with semaglutide include: Nausea (occurring in 15-44% of patients depending on dose and indication) Vomiting (5-24% of patients) Diarrhea (8-30% of patients) Constipation (11-24% of patients) Abdominal pain (5-20% of patients) These symptoms typically emerge during dose escalation and often improve over time

"It has subsided heres hoping it does for you as well." ClearTrax22 Wegovy is a prescription only medicine and may not be suitable for everyone

If you have concerns or experience persistent side effects, we can review your treatment plan and help determine the safest next step

If Wegovy cannot be tolerated despite these measures, alternative weight management medications may be considered

Other key health benefits include: Reduced risk of liver and kidney disease Improved blood pressure Lower cholesterol levels As for the weight loss benefits, these mediations work steadily

Are committed to making lifestyle changes for long-term results